Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Evolocumab Polyclonal Antibody

Catalog #:   PAJ24001 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA
Accession: CAS: 1256937-27-5
Overview

Catalog No.

PAJ24001

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

Evolocumab

Tested applications

ELISA: 1:4000-1:8000

Target

Rabbit polyclonal to AMG 145.

Specificity

The product is specific for Evolocumab. This antibody serves as an excellent positive control for Evolocumab immunogenicity (ADA) assays.

Concentration

0.5 mg/ml

Purification

Purified by antigen affinity column.

Accession

CAS: 1256937-27-5

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.

Background

Evolocumab (AMG 145) is a humanized monoclonal antibody that inhibits PCSK9 and is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease.

Data Image
References

Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE-/- mice., PMID:40462197

Association between novel agents targeting proprotein convertase subtilisin/kexin type 9 and cancer incidence., PMID:40447742

Design of the "EAST" strategy in patients with symptomatic intracranial atherosclerotic stenosis., PMID:40417113

Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis., PMID:40358978

RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: A drug-target Mendelian randomization study., PMID:40347490

Proprotein convertase subtilisin/kexin type 9 contributes to cisplatin-induced acute kidney injury by interacting with cyclase-associated protein 1 to promote megalin lysosomal degradation., PMID:40339661

Hypercholesterolemia and cardiovascular disease: the dilemma of effective treatment for target achievement according to guidelines and national healthcare policies and a call to action., PMID:40322779

LDL-C Reduction with Evolocumab Among Patients with ASCVD in China: Real-World Evidence from Tianjin Metropolitan Area., PMID:40279014

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial., PMID:40255182

Inadequate Response to PCSK9 Inhibitors., PMID:40250948

Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography., PMID:40178463

Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention., PMID:40165297

Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan., PMID:40089775

Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia., PMID:40022592

Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS., PMID:40020597

Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial., PMID:40001082

In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss., PMID:39979532

Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?, PMID:39947256

PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose., PMID:39940773

Resistance to conventional drug therapy and good response to lomitapide allowed the identification of a novel bi-allelic semi-dominant monogenic HoFH: a case report., PMID:39931866

Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes., PMID:39930254

Long-Term Lipid Lowering With Evolocumab in Older Individuals., PMID:39909681

Evolocumab for the reduction of cardiovascular risk in HIV patients: is this a clinician's best option for HIV patients?, PMID:39902591

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials., PMID:39877671

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial., PMID:39870096

Efficacy and safety of PCSK9 inhibitors in real life., PMID:39864963

Evaluation of Intensive Statins and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Intracranial Artery Plaque Stability: A Prospective Single-Arm Study., PMID:39818872

Cost-Effectiveness Analysis of Inclisiran for the Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia in Singapore., PMID:39818637

The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis., PMID:39813003

Emerging oral therapeutic strategies for inhibiting PCSK9., PMID:39802651

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression., PMID:39770423

Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China., PMID:39762992

Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial., PMID:39755915

Homozygous Familial Hypercholesterolemia Treatment: New Developments., PMID:39751968

Comprehensive Assessment of PCSK9 Inhibitors for Lipid Management: Scientific Guidance Based on Drug Selection Recommendations for Chinese Medical Institutions., PMID:39741915

Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab., PMID:39718423

Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers., PMID:39696834

Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review., PMID:39679827

Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies., PMID:39649377

PCSK9 promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagy., PMID:39632291

Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study., PMID:39585798

Inhibition of PCSK9 Protects against Cerebral Ischemia‒Reperfusion Injury via Attenuating Microcirculatory Dysfunction., PMID:39548030

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors as Adjunct Therapy to Statins: A New Frontier in Cardiovascular Risk Reduction., PMID:39539858

Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia., PMID:39531353

Causes and Management Strategies for Unusual Hypoglycemia: a Case Series., PMID:39506579

Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome., PMID:39484117

Safety and Effectiveness of Low-Density Lipoprotein Cholesterol-Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real-World, Postmarketing, Single-Arm Study., PMID:39470058

Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis., PMID:39459433

Sex differences in LDL-C reduction response to evolocumab: A propensity score matching analysis., PMID:39441027

Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial., PMID:39430462

Datasheet
$ 354
Product specifications
50 μg 354 100 μg 680

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Evolocumab Polyclonal Antibody [PAJ24001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only